�����ƽ��

As of 2017, Swiss-based pharmaceutical company Roche was the global leader in the in vitro diagnostics (IVD) market, generating over ** billion U.S. dollars in revenues in this segment. According to projections, Roche will maintain the leading position until 2024, exceeding ** billion dollars. Roche’s major competitors are Abbott Laboratories and Danaher from the United States. Among the top 10 companies, U.S. company Exact Sciences from Wisconsin is expected to have the most impressive growth, increasing its IVD revenues nearly sevenfold between 2017 and 2024.

What are in vitro diagnostics?

In vitro diagnostics allow for medical professionals to get information about diseases, conditions, and infections. These tests can be conducted within a laboratory and sometimes within a patient's home. IVDs are a large subgroup of medical devices which can range in size from small handheld devices to large complex laboratory instruments. In general, samples derived from the human body are examined ‘in vitro’ – meaning “in the glass” – for purposes of screening, diagnosis, or monitoring. Today, most medical treatments are based on IVD outcomes. IVDs are also essential for the increasing personalization of medical treatments.

Roche Diagnostics

The Roche Group from Switzerland is one of the top global pharmaceutical companies. Nevertheless, the company has also a strong medical device division - Roche Diagnostics – which is mainly represented by in vitro diagnostics. Among the best-known and best-selling diagnostic devices by Roche are devices from the cobas series, used in immunodiagnostics, clinical chemistry, and virology.